Successfully Treating Hypercalcemia Secondary to Subcutaneous Fat Necrosis With Pamidronate: A Case Series
Abstract
Subcutaneous fat necrosis (SCFN) is an unusual source of hypercalcemia in neonates. This condition is self-limiting; however, hypercalcemia can occur as a sequela. Severe hypercalcemia can result in increased morbidity and mortality. Several modalities of treatment for hypercalcemia subsequent to SCFN have been explored, including the use of bisphosphonates, particularly pamidronate. We briefly review SCFN, recognition of this uncommon dermatological phenomenon, as well as hypercalcemia resultant from SCFN and its current management strategy. Furthermore, we report a case series of two patients treated successfully with intravenous pamidronate in conjunction with other treatment modalities. Int J Clin Pediatr. 2021;10(1):6-9 doi: https://doi.org/10.14740/ijcp420
Read the paper
Related studies
- In silico strategies for modeling RNA aptamers and predicting binding sites of their molecular targets
- Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery
- Anti-phytopathogenic and plant growth promoting potential of endophytic fungi isolated from Dysoxylum gotadhora
- Mercury toxicity causes iron and sulfur deficiencies along with oxidative injuries in alfalfa (Medicago sativa)
- Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo
- Assessing the Protective Effect of Moringa oleifera Extract against Bone Metastasis: An In Vitro Simulated Digestion Approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.